The management of allergic diseases in children during the SARS-CoV-2 pandemic

IF 0.2 Q4 ALLERGY Alergologia Polska - Polish Journal of Allergology Pub Date : 2020-01-01 DOI:10.5114/pja.2020.97661

M. Baut, Jadwiga Biela-Mazur, Anna Czyżewska-Dudek, R. Kurzawa

{"title":"The management of allergic diseases in children during the SARS-CoV-2 pandemic","authors":"M. Baut, Jadwiga Biela-Mazur, Anna Czyżewska-Dudek, R. Kurzawa","doi":"10.5114/pja.2020.97661","DOIUrl":null,"url":null,"abstract":"The article presents and summarizes the current state of knowledge about the management and treatment of allergic diseases in children during the SARS-CoV-2 pandemic Patients with allergic diseases do not show different symptoms of COVID-19 Children with atopy, like most children, undergo this infection mildly Current recommendations of Polish and international societies recommend continuing the therapy of allergic diseases to minimize the adverse effects of discontinuing treatment Continuing treatment with inhaled and oral glucocorticosteroids, antihistamines and anti-leukotriene drugs is not a risk factor for SARS-CoV-2 infection and should not be stopped Effective treatment of allergic rhinitis may have a positive effect on reducing the transmission of the virus For children with atopic dermatitis it is essential to use barrier preparations to care atopic skin more often to minimize side effects of excessive use of soaps and disinfectant fluids It is not recommended to start immunotherapy with inhaled allergens during a pandemic If there are conditions for epidemiologically safe continuation of specific immunotherapy, the sublingual form is preferred To minimize the risk of transmission of SARS-CoV-2 infection in medical facilities, telemedicine is the preferred method for continuing specialist care","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5114/pja.2020.97661","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alergologia Polska - Polish Journal of Allergology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pja.2020.97661","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 1

Abstract

The article presents and summarizes the current state of knowledge about the management and treatment of allergic diseases in children during the SARS-CoV-2 pandemic Patients with allergic diseases do not show different symptoms of COVID-19 Children with atopy, like most children, undergo this infection mildly Current recommendations of Polish and international societies recommend continuing the therapy of allergic diseases to minimize the adverse effects of discontinuing treatment Continuing treatment with inhaled and oral glucocorticosteroids, antihistamines and anti-leukotriene drugs is not a risk factor for SARS-CoV-2 infection and should not be stopped Effective treatment of allergic rhinitis may have a positive effect on reducing the transmission of the virus For children with atopic dermatitis it is essential to use barrier preparations to care atopic skin more often to minimize side effects of excessive use of soaps and disinfectant fluids It is not recommended to start immunotherapy with inhaled allergens during a pandemic If there are conditions for epidemiologically safe continuation of specific immunotherapy, the sublingual form is preferred To minimize the risk of transmission of SARS-CoV-2 infection in medical facilities, telemedicine is the preferred method for continuing specialist care

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

SARS-CoV-2大流行期间儿童过敏性疾病的管理

本文对SARS-CoV-2大流行期间儿童变应性疾病的管理和治疗现状进行了介绍和总结，变应性疾病患者与大多数儿童一样，没有表现出不同的COVID-19症状。轻度感染波兰和国际协会目前建议继续治疗过敏性疾病，以尽量减少停止治疗的不良影响继续使用吸入和口服糖皮质激素治疗，抗组胺药和anti-leukotriene药物不是SARS-CoV-2感染的危险因素,不应停止有效的治疗过敏性鼻炎,起到了积极的作用对减少病毒传播的儿童特应性皮炎有必要更多的使用障碍准备治疗过敏性皮肤的副作用降到最低过度使用肥皂和消毒液体不建议开始与大流行期间吸入过敏原免疫疗法在流行病学上，有条件安全地继续进行特异性免疫治疗，首选舌下形式。为了尽量减少在医疗机构中传播SARS-CoV-2感染的风险，远程医疗是继续专科护理的首选方法

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Alergologia Polska - Polish Journal of Allergology ALLERGY-

自引率

50.00%

发文量

期刊介绍： Alergologia Polska - Polish Journal of Allergology is aimed mainly at allergologists, but also medical doctors working in related fields, such as otolaryngology, pulmonology, and dermatology. The main goal of the journal is to ensure rapid publication of important research papers and interesting case studies from the following areas: allergology, diagnostics, therapy of allergic diseases, in particular in the area of immunotherapy, rhinitis, asthma. The Editorial Board accepts for publication original papers, case studies and letters to the Editor. We also publish review articles (both commissioned and those agreed upon with the Editor-in-Chief), articles dealing with standards of medical practice, as well as special issues. The journal is published quarterly. We guarantee short review times (up to two weeks) and immediate publication on-line upon Editor acceptance.